JP2020511931A5 - - Google Patents

Download PDF

Info

Publication number
JP2020511931A5
JP2020511931A5 JP2018565824A JP2018565824A JP2020511931A5 JP 2020511931 A5 JP2020511931 A5 JP 2020511931A5 JP 2018565824 A JP2018565824 A JP 2018565824A JP 2018565824 A JP2018565824 A JP 2018565824A JP 2020511931 A5 JP2020511931 A5 JP 2020511931A5
Authority
JP
Japan
Prior art keywords
nucleic acid
recombinase
double
genome
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2018565824A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020511931A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/000967 external-priority patent/WO2018229521A1/en
Publication of JP2020511931A publication Critical patent/JP2020511931A/ja
Publication of JP2020511931A5 publication Critical patent/JP2020511931A5/ja
Abandoned legal-status Critical Current

Links

JP2018565824A 2016-06-16 2017-06-16 改良された遺伝子編集 Abandoned JP2020511931A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662350941P 2016-06-16 2016-06-16
PCT/IB2017/000967 WO2018229521A1 (en) 2016-06-16 2017-06-16 Improved gene editing
US62/350,941 2017-06-16

Publications (2)

Publication Number Publication Date
JP2020511931A JP2020511931A (ja) 2020-04-23
JP2020511931A5 true JP2020511931A5 (https=) 2020-07-30

Family

ID=65019181

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018565824A Abandoned JP2020511931A (ja) 2016-06-16 2017-06-16 改良された遺伝子編集

Country Status (7)

Country Link
US (2) US11708588B2 (https=)
EP (1) EP3472329A1 (https=)
JP (1) JP2020511931A (https=)
CN (1) CN109790551A (https=)
CA (1) CA3028074A1 (https=)
CL (1) CL2018003649A1 (https=)
WO (1) WO2018229521A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020284581A1 (en) * 2019-05-29 2021-12-23 Monsanto Technology Llc Directed genome engineering using enhanced targeted editing technologies
CN112979821B (zh) * 2019-12-18 2022-02-08 华东师范大学 一种提高基因编辑效率的融合蛋白及其应用
CN111518220A (zh) * 2020-05-14 2020-08-11 重庆英茂盛业生物科技有限公司 一种融合蛋白及其设计方法
CN111909961B (zh) * 2020-08-21 2022-04-19 华侨大学 一种CRISPR/Cas介导的ATL细胞基因编辑载体及其应用
CN116471929A (zh) * 2020-11-06 2023-07-21 香港大学 可转移的I-F型CRISPR-Cas基因组编辑系统

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
DE122007000007I1 (de) 1986-04-09 2007-05-16 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991017424A1 (en) 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7868149B2 (en) 1999-07-20 2011-01-11 Monsanto Technology Llc Plant genome sequence and uses thereof
US6603061B1 (en) 1999-07-29 2003-08-05 Monsanto Company Agrobacterium-mediated plant transformation method
JP4551058B2 (ja) 2001-01-10 2010-09-22 ロンザ・ケルン・アーゲー モジュラートランスフェクション系
US20090100536A1 (en) 2001-12-04 2009-04-16 Monsanto Company Transgenic plants with enhanced agronomic traits
US8889394B2 (en) 2009-09-07 2014-11-18 Empire Technology Development Llc Multiple domain proteins
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit
BR112013021785A8 (pt) * 2011-02-25 2018-07-03 Recombinetics Inc animais geneticamente modificados e métodos para fazer os mesmos
EP2895620B1 (en) * 2012-09-11 2017-08-02 Life Technologies Corporation Nucleic acid amplification
CA2889502A1 (en) * 2012-10-30 2014-05-08 Recombinetics, Inc. Control of sexual maturation in animals
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
US8697359B1 (en) * 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
EP3011030B1 (en) 2013-06-17 2023-11-08 The Broad Institute, Inc. Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
MX2016007325A (es) 2013-12-12 2017-07-19 Broad Inst Inc Composiciones y metodos de uso de sistemas crispr-cas en desordenes debidos a repeticion de nucleotidos.
CN104946621A (zh) 2014-03-28 2015-09-30 中国科学院上海生命科学研究院 基因敲入组合物及其使用方法和应用
EP3686279B1 (en) * 2014-08-17 2023-01-04 The Broad Institute, Inc. Genome editing using cas9 nickases
WO2016054326A1 (en) * 2014-10-01 2016-04-07 The General Hospital Corporation Methods for increasing efficiency of nuclease-induced homology-directed repair
CA2963820A1 (en) * 2014-11-07 2016-05-12 Editas Medicine, Inc. Methods for improving crispr/cas-mediated genome-editing
EP3851530A1 (en) * 2015-03-26 2021-07-21 Editas Medicine, Inc. Crispr/cas-mediated gene conversion
US9988637B2 (en) * 2015-10-26 2018-06-05 National Tsing Hua Univeristy Cas9 plasmid, genome editing system and method of Escherichia coli

Similar Documents

Publication Publication Date Title
JP7698828B2 (ja) Rnaを編集する方法および組成物
CN103224947B (zh) 一种基因打靶系统
KR101785847B1 (ko) 선형 이중가닥 DNA를 활용한 CRISPR/Cas9 시스템을 이용한 표적 유전체 교정
JP2016500262A5 (https=)
JP2016504026A5 (https=)
JP2016165307A5 (https=)
JP2020511931A5 (https=)
US20190119678A1 (en) Means and methods for inactivating therapeutic dna in a cell
JP2019115348A5 (https=)
Yuan et al. A marker-free system for highly efficient construction of vaccinia virus vectors using CRISPR Cas9
Cao et al. The multiplexed CRISPR targeting platforms
AU2018222092A1 (en) Genome editing system and method
JP2015510778A5 (https=)
CN107794272A (zh) 一种高特异性的crispr基因组编辑体系
Jo et al. CRISPR/Cas9 system as an innovative genetic engineering tool: Enhancements in sequence specificity and delivery methods
CN104805078A (zh) 用于高效基因组编辑的rna分子的设计、合成及其应用
WO2017215648A1 (zh) 基因敲除方法
EP3733842A1 (en) System and method for genome editing
JP2020519304A5 (https=)
CN107151677B (zh) 基于CRISPR/Cas9多基因敲除低转染效率细胞系的方法
CN102703424B (zh) 一种重组工程介导的大肠杆菌基因组点突变的方法
JP2020527938A (ja) デザイナーdna組換え酵素を利用したゲノムを遺伝的に改変するための方法及び手段
Bayat et al. The CRISPR growth spurt: from bench to clinic on versatile small RNAs
KR20240107373A (ko) C2c9 뉴클레아제 기반의 신규 게놈 편집 시스템 및 이의 응용
CN105543223A (zh) 一种基于miRNA/shRNA转录加工机制转录sgRNA的方法